Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CYCC 
Cyclacel Pharmaceuticals Inc (CYCC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: CYCC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -74.73% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 55.38M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 512584 | Beta 0.28 | 52 Weeks Range 0.22 - 4.00 | Updated Date 04/1/2025 |
52 Weeks Range 0.22 - 4.00 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -27.4 |
Earnings Date
Report Date 2025-03-17 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -21770% |
Management Effectiveness
Return on Assets (TTM) -108.63% | Return on Equity (TTM) -807.39% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 52401052 | Price to Sales(TTM) 748.42 |
Enterprise Value 52401052 | Price to Sales(TTM) 748.42 | ||
Enterprise Value to Revenue 708.12 | Enterprise Value to EBITDA 0.02 | Shares Outstanding 205884992 | Shares Floating 1319936 |
Shares Outstanding 205884992 | Shares Floating 1319936 | ||
Percent Insiders 94.59 | Percent Institutions 0.35 |
Analyst Ratings
Rating 3 | Target Price 12.25 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cyclacel Pharmaceuticals Inc
Company Overview
History and Background
Cyclacel Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines for cancer and other proliferative diseases. Founded in 1996, the company has primarily focused on cyclin-dependent kinase (CDK) inhibitors. Over the years, Cyclacel has advanced various compounds through preclinical and clinical development stages.
Core Business Areas
- Drug Discovery and Development: Focuses on identifying and developing novel therapeutics targeting cellular processes driving cancer. Primary focus is on hematological malignancies and solid tumors.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of their drug candidates.
- Licensing and Partnerships: Seeks partnerships to further develop and commercialize their drug candidates.
Leadership and Structure
The leadership team includes Spiro Rombotis (President & CEO). The company has a board of directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- Fadraciclib: Fadraciclib is a CDK2/9 inhibitor in clinical development for hematological malignancies. The competitive landscape includes other CDK inhibitors developed by companies like Novartis and Eli Lilly. No market share data for this investigational compound.
- CYC140: CYC140 is a selective SAC inhibitor that aims to target cancer cells and disrupt cell division.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant investments in research and development. Focus areas include targeted therapies and immuno-oncology. Regulatory hurdles and lengthy development timelines are key challenges.
Positioning
Cyclacel is a smaller player in the biopharmaceutical industry, focusing on niche areas within oncology with promising novel mechanism of action inhibitors.
Total Addressable Market (TAM)
The TAM for oncology drugs is substantial, projected to reach hundreds of billions of dollars. Cyclacel, focusing on CDK inhibition and SAC inhibition, targets specific segments within this larger market, and its positioning is tied to the success of its clinical trials and market approvals.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting key cancer pathways
- Experienced management team
- Intellectual property protection
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial outcomes
- High risk of drug development failure
Opportunities
- Partnerships and licensing agreements
- Expansion into new therapeutic areas
- Positive clinical trial results leading to market approval
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Clinical trial failures
Competitors and Market Share
Key Competitors
- NVS
- LLY
Competitive Landscape
Cyclacel faces intense competition from larger, well-funded pharmaceutical companies. Their success depends on demonstrating superior efficacy and safety of their drug candidates in specific cancer subtypes.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on clinical trial progress and funding. Detailed analysis requires financial data.
Future Projections: Future growth depends on clinical trial success, regulatory approvals, and market adoption of their drugs. Analyst estimates are needed for projections.
Recent Initiatives: Recent initiatives include advancing fadraciclib in clinical trials and exploring partnerships for CYC140 and other assets.
Summary
Cyclacel is a small biopharmaceutical company with a focus on novel cancer therapies. The company's strength lies in its drug candidates and scientific expertise, but it faces challenges related to funding and competition. Clinical trial outcomes and partnerships will be critical to its future success. They should look out for larger pharmaceutical companies eating into the same science they are exploring.
Similar Companies
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
NVS
Novartis AG ADR
NVS
Novartis AG ADR
Sources and Disclaimers
Data Sources:
- Cyclacel Pharmaceuticals Inc. website
- SEC filings (10-K, 10-Q)
- Company press releases
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. The information provided is not guaranteed to be exhaustive or accurate. Investment decisions should be made based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cyclacel Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Berkeley Heights, NJ, United States | ||
IPO Launch date 2004-05-05 | CEO & Executive Director Dr. Sing Ee Wong | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.cyclacel.com |
Full time employees - | Website https://www.cyclacel.com | ||
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.